[Oral antidiabetics of the sulfonylurea group and their problems in therapy].
By the abolition of biguanids as oral antidiabetics the importance of derivatives of sulfonylcarbamids became prominent in the treatment of diabetic elderly patients. Because of the properties of that group, there are a number of problems by the therapy with these derivatives. There is the mostly existing multimorbidity in geriatric patients with the risk of incompatibilities of drugs in cause of multitherapy and there is the influence of morbid states on the pharmacokinetics. Some of the various questions will be shortly described in this article. There are then given also practical advices for the relations with the derivatives of sulfonylcarbamids in treating diabetic patients.
D000284:Administration, Oral; D000368:Aged; D003920:Diabetes Mellitus / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D007700:Kinetics; D013453:Sulfonylurea Compounds / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds
Orale Antidiabetika aus der Gruppe der Sulfonylharnstoffderivate und ihre Problematik in der Therapie.